Human immunodeficiency virus type 1 (hiv-l) viremia changes and development of drug-related mutations in patients with symptomatic hiv-l infection receiving alternating or simultaneous zidovudine and didanosine therapy

Journal of Infectious Diseases

Volumn 171, Issue 5, 1995, Pages 1152-1158

  Kojima, Eiji ^a,b,c,d   Shirasaka, Takuma ^a,b,c   Anderson, Barry D ^a,b,c   Anderson, Sudhichai ^a,b,c   Steinberg, Seth M ^a,b,c   Broder, Samuel ^a,b,c   Yarchoan, Roberte ^a,b,c   Mitsuya, Hiroaki ^a,b,c  

^a Medical Branch   (United States)

^b Biostatistics and Data Management Section   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NIPPON PAPER INDUSTRIES CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; IMMUNOGLOBULIN G; LEUCINE; VALINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CODON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIREMIA; VIRUS PARTICLE;

ADULT; BASE SEQUENCE; CD4 LYMPHOCYTE COUNT; CODON; DIDANOSINE; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; GENES, POL; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; RNA, VIRAL; VIREMIA; ZIDOVUDINE;

EID: 0028909530     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/171.5.1152     Document Type: Article

References (33)

1. Mitsuya H, Yarchoan R. Development of antiretroviral therapy for AIDS and related disorders. In: Broder S, Merigan T, Bolognesi D, eds. Textbook of AIDS medicine. Baltimore: Williams & Wilkins, 1994:721-42
2. Yarchoan R, Lietzau JA, Nguyen BY, et al. A randomized pilot study of alternating and simultaneous regimens of zidovudine (AZT) and di-danosine (didanosine) in patients with symptomatic human immunodeficiency virus (HIV) infection. J Infect Dis 1993;169:9-17
3. Yarchoan R, Venzon DJ, Pluda JM, et al. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med 1991; 115:184-9
4. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-60
5. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type I infection. N Engl J Med 1991;324:961-4
6. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8
7. Embertson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-62
8. Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993;328:327-35
9. Aoki S, Yarchoan R, Thomas RV, et al. Quantitative analysis of HIV-1proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of pibviral DNA content following treatment with 2', 3'-dideoxyinosine. AIDS Res Hum Retroviruses 1990;6:1331-9
10. Holodniy M, Katzenstein DA, Sengupta S, et al. Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis 1991;163:862-6
11. Lu W, Grassi F, Tourani JM, et al. High concentration of peripheral blood mononuclear cells harboring infectious virus correlates with rapid progression of human immunodeficiency virus type l-related diseases. J Infect Dis 1993:168:1165-8
12. Aoki-Sei S, Yarchoan R, Kageyama S, et al. Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction. AIDS Res Hum Retroviruses 1992;8:1269-76
13. Piatak MJ, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-54
14. Shirasaka T, Yarchoan R, O'Brien M. et al. Changes in drug-sensitivity of human immunodeficiency virus type 1 during therapy with azi-dothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci USA 1993;90:562-6
15. Nunberg JH, Schleif WA, Boots EJ, et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 1991;65:4887-92
16. Wain-Hobson S, Vartanian JP, Henry M, et al. LAV revised: origins of the early HIV-1 isolates from Institut Pasteur. Science 1991; 252:961-5
17. Chomczynski P, Nicoletta S. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9
18. Ou CY, Kwok S, Mitchell SW, et al. DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science 1988;239:295-7
19. Kageyama S, Hoekzema DT, Murakawa Y, et al. A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits the infectivity of HIV-1 in vitro. AIDS Res Hum Retroviruses 1994;10:723-31
20. Anderson BD, Shirasaka T, Kojima E, Yarchoan R, Mitsuya H. Identification of drug related genotypic changes in HIV-1 from serum using the selective polymerase chain reaction. Antiviral Res 1994;25:245-58
21. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-8
22. St. Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to didanosine and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-9
23. Yarchoan R, Perno CF, Thomas RV, et al. Phase I studies of 2', 3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988;1:76-81
24. Husson RN, Shirasaka T, Butler KM, Pizzo PA, Mitsuya H. High level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy. J Pediatr 1993;123:9-16
25. Collier AC, Coombs RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HI V-1 infection. Ann Intern Med 1993; 119:786-93
26. Holodniy M, Katzenstein D, Winters M, et al. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. J Acquir Immune Defic Syndr 1993;6:366-9
27. Gao WY, Shirasaka T, Johns DG, Broder S, Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, dideoxyinosine in activated and resting peripheral blood mononuclear cells. J Clin Invest 1993;91:2326-33
28. Gao WY, Agbaria R, Driscoll JS, Mitsuya H. Divergent antiviral activity and anabolic phosphorylation of 2', 3'-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994;269:12633-8
29. Perno CF, Yarchoan R, Cooney DA, et al. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymi-dine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989;169:933-51
30. Perno CF, Cooney DA, Gao WY, et al. Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocytes/macrophages. Blood 1992;80:995-1003
31. White EL, Parker WB, Ross LJ, Shannon WM. Lack of synergy in the inhibition of HI V-1 reverse transcriptase by combination of the 5'-tri-phosphates of various anti-HIV nucleoside analogs. Antiviral Res 1993;22:295-308
32. Richman DD, Meng TC, Spector SA, et al. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1994;7:135-8
33. Shafer RW, Kozal MJ, Winters MA, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of polgene mutations. J Infect Dis 1994;169:722-9